Redeye maintains its base case of SEK 265 per share after the news that Eisai has initiated a rolling submission for Biologics license application under the accelerated approval pathway - for lecanemab. We expected it, and based on the high quality clinical data from phase II, good safety and efficacy profile, we are positive to the outcome of this application.